Details for Patent: 6,667,042

Title:	Fluroquinilone antibiotic product, use and formulation thereof
Abstract:	An antibiotic product, in particular a fluroquinilone such as ciprofloxacin, is comprised of at least three dosages forms, each of which has a different release profile, with the C.sub.max for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a C.sub.max at different times.
Inventor(s):	Rudnic; Edward M. (N. Potomac, MD), Isbister; James D. (Potomac, MD), Treacy, Jr.; Donald J. (Arnold, MD), Wassink; Sandra E. (Frederick, MD)
Assignee:	Advancis Pharmaceutical Corp. (Germantown, MD)
Filing Date:	Dec 20, 2001
Application Number:	10/027,837
Claims:	1. A once-a-day antibiotic product comprising: first, second, and third dosage forms; each of said dosage forms comprising a fluroquinilone and a pharmaceutically acceptable carrier; said first dosage form being an immediate release dosage form; said second and third dosage forms being delayed release dosage forms; wherein each of said first, second, and third dosage forms initiates release of the fluroquinilone at different times; wherein Cmax of the total fluroquinilone released from said product is achieved in less than about 12 hours from administration; and wherein said once-a-day product contains the total dosage of the fluroquinilone for a twenty-four hour period. 2. The antibiotic product of claim 1, wherein said fluroquinilone is ciprofloxacin. 3. The product of claim 2, wherein the Cmax for the product is reached no earlier than four hours after administration. 4. The product of claim 2, wherein the ciprofloxacin released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after administration of the product. 5. The product of claim 2, wherein the ciprofloxacin released from the second dosage form reaches a Cmax in no more than about 4 hours after administration of the product. 6. The product of claim 2, wherein the ciprofloxacin released from the third dosage form reaches a Cmax within 8 hours after administration of the product. 7. The product of claim 2, wherein the immediate release dosage form contains at least 20% and no more than 50% of the total dosage of ciprofloxacin. 8. The product of claim 2, wherein the product is an oral dosage form. 9. The product of claim 2, wherein the ciprofloxacin released from the second dosage form reaches a Cmax after Cmax is reached for the ciprofloxacin released from the first dosage form. 10. The product of claim 2, wherein the ciprofloxacin released from the third dosage form reaches a Cmax after Cmax is reached for the ciprofloxacin released from the second dosage form. 11. The product of claim 2 further comprising a fourth dosage form, said fourth dosage form being a delayed release dosage form comprising ciprofloxacin and a pharmaceutically acceptable carrier; and wherein ciprofloxacin released from said fourth dosage form reaches a Cmax after Cmax is achieved for ciprofloxacin released from each of said first, second, and third dosage forms. 12. The product of claim 11, wherein the Cmax for the product is reached no earlier than four hours after administration. 13. The product of claim 11, wherein the ciprofloxacin released from the first dosage form reaches a Cmax within from about 0.5 hours to about 2 hours after administration of the product. 14. The product of claim 11, wherein the ciprofloxacin released from the second dosage form reaches a Cmax in no more than about 4 hours after administration of the product. 15. The product of claim 11, wherein the ciprofloxacin released from the third dosage form reaches a Cmax within 8 hours after administration of the product. 16. The product of claim 11, wherein said second dosage form initiates release of ciprofloxacin before said third dosage form, wherein said third dosage form initiates release of ciprofloxacin before said fourth dosage form, wherein said second dosage form provides 20% to 35% by weight of the total ciprofloxacin released by said second, third, and fourth dosage forms, wherein said third dosage form provides from 20% to 40% by weight of the total ciprofloxacin released by said second, third, and fourth dosage forms, and wherein said fourth dosage form provides the remainder of the total ciprofloxacin released by said second, third, and fourth dosage forms. 17. The product of claim 11, wherein the product is an oral dosage form. 18. The product of claim 11, wherein the ciprofloxacin released from the second dosage form reaches a Cmax after Cmax is reached for the ciprofloxacin released from the first dosage form. 19. The product of claim 11, wherein the ciprofloxacin released from the third dosage form reaches a Cmax after Cmax is reached for the ciprofloxacin released from the second dosage form. 20. A process for treating a bacterial infection in a host comprising: administering to a host the product of claim 1, once-a-day. 21. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 2, once-a-day. 22. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 3, once-a-day. 23. A process for treating a bacterial infection in a host comprising: a administering to a host the ciprofloxacin product of claim 4, once-a-day. 24. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 5, once-a-day. 25. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 6, once-a-day. 26. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 7, once-a-day. 27. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 8, once-a-day. 28. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 9, once-a-day. 29. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 10, once-a-day. 30. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 11, once-a-day. 31. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 12, once-a-day. 32. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 13, once-a-day. 33. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 14, once-a-day. 34. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 15, once-a-day. 35. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 16, once-a-day. 36. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 17, once-a-day. 37. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 18, once-a-day. 38. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 19, once-a-day. 39. The product of claim 2, wherein the ciprofloxacin is in the form of a salt. 40. A process for treating a bacterial infection in a host comprising: administering to a host the ciprofloxacin product of claim 39, once-a-day.